Clinical trials: Multiple Sclerosis (MS)
Multiple Sclerosis, Relapsing-Remitting
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to…
- Trial name
- NCT01591551
- Testing
- Natalizumab (Tysabri)
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cornerstone Health Care, PA
Multiple Sclerosis, Rheumatoid Arthritis
Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis
The main objective of this study is to measure, in patients with MS or Chronic Inflammatory Arthritis (CIA), the correlation between two calcium intake assessment methods: A self assessment questionnaire of calcium intake…
- Trial name
- QALCIMUM (NCT02636829)
- Testing
- QALCIMUM questionnaire, Determination of calcium intake by a dietician interview
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, MS
Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome…
- Trial name
- NCT06957145
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Koç University
Multiple Sclerosis
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis
- Trial name
- MST3K (NCT02760056)
- Testing
- Liothyronine sodium
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
Validating a peptide-based laboratory test enabling the measurement of Tysabri® serum levels (pharmacokinetics, PK) in multiple sclerosis patients undergoing therapy.
- Trial name
- IIT12 (NCT02965170)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Rocky Mountain MS Research Group, LLC
Multiple Sclerosis, Relapsing-Remitting
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus…
- Trial name
- INCREASE (NCT03387046)
- Testing
- D-aspartate, IFN beta-1a, Methylprednisolone
- Where
- 17 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Trial name
- ZENITH (NCT07224373)
- Testing
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT
The goal of this clinical trial study is to evaluate the presence of relationships between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), apparent absence of inflammatory activity (silent…
- Trial name
- NCT05783934
- Testing
- 18F-florbetaben PET/CT
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Multiple Sclerosis (MS)
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The main objective is to explore the safety and tolerability of the universal STAR-T cell injection in patients with progressive or…
- Trial name
- NCT07523100
- Testing
- Universal STAR-T Cell Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Daishi Tian
Multiple Sclerosis
The Use of Technology to Improve MS Clinical Trials and Patient Care
Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numbness, weakness, visual problems, or other symptoms.
- Trial name
- NCT02454907
- Testing
- Communication with the clinic
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Self Efficacy
Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) Turkish Adaptation
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system. Despite functional limitations and unpredictable disease course, individuals with MS are aimed to maintain…
- Trial name
- NCT06231030
- Testing
- Validity, Reliability and Adaptation
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 176 people
- Sponsor
- Nigde Omer Halisdemir University
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses…
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
- Trial name
- NCT05029609
- Testing
- Intranasal Foralumab Solution
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis
The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis
Multiple Sclerosis (MS) is an invalidating neurological disease known to cause physical symptoms, which usually are the main focus of treatment.
- Trial name
- MS-CEBA (NCT06016309)
- Testing
- There is no intervention.
- Where
- Netherlands
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS
The purpose of the study is to determine whether giving intravenous dexamethasone every 4 weeks during the first 12 months of weekly Avonex dosing will reduce the progression of functional impairment, brain atrophy, relapse rate…
- Trial name
- NCT00232193
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Providence Multiple Sclerosis Center
Multiple Sclerosis
A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis
This study is an open-label, single-arm, run-in study in patients with RRMS treated with first line therapies (interferon-beta, glatiramer acetate, teriflunomide and dimethyl fumarate), assessing the feasibility and tolerability…
- Trial name
- FAST-MS (NCT06039007)
- Testing
- 7-day Fasting-Mimicking Diet (7-DAY FMD)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Ospedale Policlinico San Martino
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, MS
Effect of Music Therapy on Pain in People With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and progressive neurological disease of the central nervous system, often seen between the ages of 20-30.
- Trial name
- NCT06800144
- Testing
- Heart rate synchronized motor imagery music therapy, Heart rate synchronized music therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Istanbul Bilgi University
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Muscle Spasticity
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following…
- Trial name
- NCT00358293
- Testing
- Tizanidine (sublingual or oral)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Teva GTC